회사 개요
Enveric Biosciences, Inc. (ENVB) operates within the healthcare sector, specifically focusing on the biotechnology industry, where it engages in the development of small-molecule therapeutics designed to address anxiety, depression, and addiction disorders. The company's primary asset candidate, EB-002, is an active metabolite of psilocybin currently in preclinical development stages, representing a potential therapeutic intervention in the mental health space. As of the latest available data, the company maintains a market capitalization of $3.85 million and employs a workforce of 5 individuals, indicating a very early-stage organizational structure typical of pre-revenue biotech entities. The modest market cap of $3.85 million suggests that ENVB is a micro-cap stock with significant potential volatility and high risk, as it has not yet generated commercial revenue to support its operations or fund further development through organic earnings.
재무 건전성
The company reports annual revenue and net income (TTM) as N/A and $-12,131,472 respectively, while EBITDA stands at $-8,573,590, reflecting a substantial gap between top-line activity and profitability driven by high research and development expenditures common in the biotech sector. Free cash flow is reported at $-4,792,909, which indicates that the company is burning through cash reserves to fund its operations and drug development pipeline rather than generating surplus liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signifies the company has not yet achieved commercial sales volume necessary to generate revenue-based profitability. The balance sheet holds $4.68 million in cash against $0 in debt, creating a conservative capital structure that allows the firm to continue operations without the burden of interest payments or leverage constraints. With a debt-to-equity ratio listed as N/A due to zero debt, the financial profile relies entirely on equity financing to sustain its burn rate. The current ratio is 5.38, demonstrating strong short-term liquidity where current assets significantly exceed current liabilities, providing a comfortable buffer for operational expenses. Return on Equity is -304.0% and Return on Assets is -134.1%, metrics that reveal management is utilizing shareholder capital to generate significant losses, which is a standard characteristic for pre-commercial biotechnology firms but warrants close monitoring of cash runway.
밸류에이션 평가
The P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is listed as -1.45, a metric that implies the market is pricing in future earnings recovery but currently reflects the negative earnings trajectory of the trailing twelve months. The Price to Book ratio is 0.52, indicating that the company's market valuation is trading at less than half of its book value, which often signals a deep discount or significant perceived risk regarding asset realizability in the biotech sector. The Price to Sales ratio is N/A because the company has no revenue, and the EV/EBITDA stands at 0.10, suggesting an extremely low valuation multiple relative to enterprise value that does not yet account for future cash flow potential from drug approvals. The stock's 52-week high is $17.84 and the 52-week low is $1.75, placing the trading range in a highly volatile band typical for speculative biotech assets with minimal liquidity. The Beta of 0.33 indicates that the stock price exhibits significantly lower volatility relative to the broader market, moving with less sensitivity to general market fluctuations despite its small market capitalization.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, meaning there is no historical growth data available to compare earnings expansion against revenue generation, as the company has not yet crossed the threshold into commercial sales. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that all available cash and capital are being reinvested directly into research, development, and operational expansion rather than distributed to shareholders. This reinvestment strategy is necessary for a preclinical biotechnology company to advance its product candidates like EB-002 through clinical trials, but it precludes any current income generation for investors. The overall growth and income profile is characterized by a lack of current financial returns and reliance on external capital, with growth potential entirely dependent on the successful progression of its therapeutic pipeline and future market entry.